The UK Competition and Markets Authority (CMA) has accused US pharmaceutical company Merck Sharp & Dohme (MSD) of operating an anti-competitive discount scheme for its medicine Remicade.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Remicade is the brand name for MSD’s version of a biological medicine called infliximab, which is used to treat patients suffering from gastroenterology and rheumatology conditions such as Crohn’s disease, ulcerative colitis and rheumatoid arthritis.

In the provisional investigation, which opened in December 2015, CMA found that MSD violated competition law by starting the discount scheme for Remicade that can affect other ‘biosimilar’ versions of infliximab, which are comparatively new to the market.

The UK competition watchdog noted that it has completed only a provisional investigation based on preliminary findings, which should not be concluded as absolute and final.

CMA will look into the representations by MSD before determining the final verdict.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The authority has proposed to find MSD and its parent company Merck & Co., ‘jointly and severally liable for the alleged infringement’.

"In response to the provisional decision, MSD said in a statement that the company is confident the proceedings will show it has complied with competition law at all times."

In response to the provisional decision, MSD said in a statement that the company is confident the proceedings will show it has complied with competition law at all times.

The company noted that the discounts on Remicade were competitively priced and offered savings to the UK National Health Service (NHS) without affecting competition.

MSD also stated that it is fully cooperating with the CMA in the ongoing investigation.

Headquartered in Kenilworth, New Jersey, MSD focuses on developing medicines and vaccines for challenging diseases.

Image: The UK Competition and Markets Authority (CMA) sets out its provisional findings relating to discounts offered by MSD on sales of Remicade (infliximab). Photo: © Crown copyright.